Spectral Receives UKCA Authorization for Burn Indication Expected Commercialization 2nd Half 2024

4 months ago

DALLAS, Feb. 22, 2024 (GLOBE NEWSWIRE) -- Spectral AI, Inc. (Nasdaq: MDAI) (“Spectral AI” or the “Company”), an artificial intelligence…

Nautilus Biotechnology to Participate in the TD Cowen 44ᵗʰ Annual Healthcare Conference

4 months ago

SEATTLE, Feb. 22, 2024 (GLOBE NEWSWIRE) -- Nautilus Biotechnology, Inc. (NASDAQ: NAUT; or “Nautilus”), a company pioneering a single-molecule protein…

Lisata Therapeutics to Host Year-End 2023 Conference Call on Thursday, February 29, 2024 at 4:30 p.m. Eastern Time

4 months ago

BASKING RIDGE, N.J., Feb. 22, 2024 (GLOBE NEWSWIRE) -- Lisata Therapeutics, Inc. (Nasdaq: LSTA) (“Lisata” or the “Company”), a clinical-stage…

Notice of Nexstim Plc’s 2023 Full Year Results

4 months ago

Press release, Helsinki, 22 February 2024 at 3 PM (EET) Notice of Nexstim Plc’s 2023 Full Year Results Nexstim Plc…

Soleno Therapeutics to Present at the TD Cowen 44th Annual Health Care Conference

4 months ago

REDWOOD CITY, Calif., Feb. 22, 2024 (GLOBE NEWSWIRE) -- Soleno Therapeutics, Inc. (“Soleno”) (NASDAQ: SLNO), a clinical-stage biopharmaceutical company developing…

Motus GI Holdings, Inc. Announces Exercise of Warrants for $2.7 Million Gross Proceeds

4 months ago

FORT LAUDERDALE, Fla., Feb. 22, 2024 (GLOBE NEWSWIRE) -- Motus GI Holdings, Inc. (Nasdaq: MOTS, or “Motus” or “the Company”),…

BioAdaptives, Inc. Announces NaturaComplete™, an All-In-One Supplement to Optimize Its AI-Based FYO Obesity Management System

4 months ago

LAS VEGAS, NV, Feb. 22, 2024 (GLOBE NEWSWIRE) -- via NewMediaWire – BioAdaptives, Inc. (OTC: BDPT), a leading manufacturer and…

MedBright AI Announces Limmi Disease Insights Platform Being Used in University Hospital Setting to Improve Detection of Kidney Stone Disease Recurrence

4 months ago

VANCOUVER, British Columbia, Feb. 22, 2024 (GLOBE NEWSWIRE) -- MedBright AI Investments Inc. (the “Company” or “MedBright”) (CSE:MBAI, OTCQB:MBAIF) is…

Tarsus Announces Positive Topline Results from Carpo, a Phase 2a Proof-of-Concept “Tick-Kill” Trial Evaluating TP-05 (lotilaner) for the Prevention of Lyme Disease

4 months ago

TP-05 demonstrated tolerability and statistically significant tick mortality, suggesting potential for on-demand Lyme disease prophylaxisIRVINE, Calif., Feb. 22, 2024 (GLOBE…

Notable Advances Volasertib Phase 2 Program Utilizing Proprietary Predictive Precision Medicine Platform-Guided Enrollment

4 months ago

Predictive Precision Medicine Platform (PPMP) utilized to enrich program for clinically responding patients and reduce the risk, time, and cost…